Promising results have been reported for B7-H3-directed antibody-drug conjugates, such as YL201 and HS-20093, with notable objective response rates across multiple tumor types.77,78 Early clinical signals have also led to FDA Breakthrough Therapy Designation for agents such as GSK5764227. The gene discussed is CD276; the disease is neoplasm.